Study details
Enrolling now
Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults
Southwest Autism Research & Resource Center
NCT IDNCT06526208ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
108
Study length
about 3 years
Ages
18–45
Locations
1 site in AZ
About this study
Researchers are testing whether a marijuana-based drug helps with anxiety in autistic adults. The trial is comparing the drug to a placebo (an inactive substance) to see if it reduces symptoms of anxiety. Participants will take the drug or placebo daily for 8 weeks, keeping a diary and attending clinic visits.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take MB-IMP
PhasePhase 2
Primary goalChange in baseline on reported anxiety related symptoms
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change in baseline on reported anxiety related symptoms
Body systems
Psychiatry / Mental Health